Welcome to our dedicated page for PMGC Holdings SEC filings (Ticker: ELAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PMGC Holdings Inc. filings document material events, subsidiary announcements, capital-structure disclosures, material agreements, governance matters, and Nasdaq-listed common stock information. Recent Form 8-K reports include Regulation FD disclosures and press-release exhibits related to NorthStrive Biosciences, NorthStrive Defense Tech, AGA Precision Systems, SVM Machining, Pacific Sun Packaging, and corporate financing activity.
The company’s regulatory record identifies PMGC as a Nevada corporation with common stock listed on The Nasdaq Stock Market under the symbol ELAB and as an emerging growth company. Filing categories also cover shareholder voting matters, operating and financial results, security-structure information, and subsidiary-level developments involving manufacturing agreements, intellectual property, packaging markets, and defense technology initiatives.
PMGC Holdings Inc. is asking stockholders to vote at its 2026 virtual annual meeting on four proposals, including electing five directors and amending its bylaws to introduce a staggered board with Class I three-year terms and Class II one-year terms starting in 2027.
Stockholders will also vote on ratifying HTL as independent auditor for the year ending December 31, 2026, and on allowing adjournment of the meeting to solicit additional proxies if support for key proposals is insufficient. Holders of 4,543,751 common shares and 6,372,874 Series B preferred shares as of April 27, 2026 may vote, with all share figures retrospectively adjusted for two 2026 reverse stock splits that together equal a 1-for-24 split.
PMGC Holdings Inc. reports first-quarter 2026 results showing an early revenue base alongside heavy losses and dependence on external financing. Revenue from newly acquired subsidiaries reached $681,994, mainly from IT packaging and precision machining, producing gross profit of $230,474 and a gross margin of about one-third.
The company posted a net loss of $4,967,259 from continuing operations and has an accumulated deficit of $25,984,699. Management explicitly states that recurring losses, negative operating cash flow and reliance on financing raise substantial doubt about its ability to continue as a going concern, though the financial statements assume it will.
Liquidity improved in the quarter due to aggressive use of an equity line of credit. Cash rose to $14,354,374 as PMGC drew $14,093,737 of pre-paid equity financing and issued over 1.8 million shares to settle related convertible obligations. At March 31, 2026, working capital was $5,088,853, total assets were $26,033,318, and total liabilities were $13,426,865. The company also closed the acquisition of SVM Machining for total consideration of about $3.0 million and continues to build a multi-subsidiary platform in aerospace, defense and packaging while managing significant convertible debt and derivative warrant liabilities.
PMGC Holdings Inc. completed the acquisition of 100% of A&B Aerospace, Inc. for $4.5 million in cash, paying $4.275 million at closing and retaining $225,000 as an indemnification holdback tied to specific litigation. The price is subject to cash and net working capital adjustments after closing.
A&B Aerospace is a precision CNC machining contractor serving aerospace, defense, and industrial markets. It generated $4.28 million of revenue and a $0.11 million net loss in the year ended May 31 2025, and $3.61 million of revenue with $0.34 million net income for the nine months ended February 28 2026. As of February 28 2026, it reported total assets of $2.41 million, cash of $0.68 million, investments of $0.34 million, and net working capital of about $1.45 million, indicating a solid liquidity position.
PMGC Holdings Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 5, 2026. The company asks shareholders of record as of April 27, 2026 to vote on four proposals: election of five directors, an amendment to adopt a staggered board, ratification of HTL as auditor, and authorization to adjourn to solicit additional proxies. The Proxy Statement notes combined reverse stock splits that effect a 1:24 retrospective adjustment to share and derivative counts, discloses executive compensation arrangements (including a consultant fee to GB Capital of $300,000 per annum for the CEO), and describes the 2025 Equity Incentive Plan reserve and governance procedures.
PMGC Holdings Inc. furnished an Information Statement to report shareholder actions taken by written consent on April 23, 2026. The Majority Shareholders approved an amendment to the 2025 Equity Incentive Plan to increase plan shares to 1,112,636 and approved a Certificate of Amendment to raise authorized capital to 1,500,000,000 shares (1,000,000,000 Common; 500,000,000 Preferred). The Written Consent was adopted by holders of 40 Common shares and 6,372,874 Series B Preferred shares, representing approximately 58.37% of voting power as of the April 23, 2026 record date. The corporate actions will be effective no earlier than twenty calendar days after mailing of the Information Statement and, for the Authorized Shares Increase, at a time set by the CEO in his discretion subject to the stated conditions.
PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Biosciences Inc., reported that NorthStrive has filed a new U.S. patent application covering its EL-22 myostatin-engineered probiotic for human pharmaceutical use. The application (U.S. Application No. 19/655,160) focuses on formulated products, dosing regimens and protections for treating a broad range of muscle-wasting conditions, including sarcopenia, muscle disuse atrophy and certain neurological disorders. This filing builds on earlier EL-22 intellectual property aimed at muscle preservation and growth, including in patients receiving GLP-1 receptor agonist weight-loss treatments, and is intended to strengthen NorthStrive’s muscle health therapeutics portfolio.
PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Biosciences Inc., reported that NorthStrive has filed a new U.S. patent application covering its EL-22 myostatin-engineered probiotic for human pharmaceutical use. The application (U.S. Application No. 19/655,160) focuses on formulated products, dosing regimens and protections for treating a broad range of muscle-wasting conditions, including sarcopenia, muscle disuse atrophy and certain neurological disorders. This filing builds on earlier EL-22 intellectual property aimed at muscle preservation and growth, including in patients receiving GLP-1 receptor agonist weight-loss treatments, and is intended to strengthen NorthStrive’s muscle health therapeutics portfolio.
PMGC Holdings Inc. informed shareholders that its Majority Shareholders approved, by written consent, entry into an equity line of credit and related Transaction Documents that permit up to $40,000,000 of aggregate Pre-Paid Purchases. The company completed an Initial Pre-Paid Purchase with an original principal balance of $10,730,000, received net proceeds of $9,927,380, and delivered 262,467 Registered Shares for $1,000,000. The Written Consent authorizes issuances in excess of Nasdaq Listing Rule 5635(d) limits; issuances subject to a 20-calendar-day waiting period after mailing. Shares outstanding as of the Record Date were 4,188,080 common and 6,372,874 Series B preferred.
PMGC Holdings Inc. furnished an Information Statement reporting that holders with a written consent approved two corporate actions: an amendment to the 2025 Equity Incentive Plan increasing plan authorizations to 1,112,636 shares, and an amendment to the Articles of Incorporation increasing authorized capital stock to 1,500,000,000 shares (1,000,000,000 Common; 500,000,000 Preferred).
The Written Consent was adopted by shareholders holding a majority of the voting power as of the Record Date of April 23, 2026. The consenting holders reported ownership of 40 shares of Common Stock and 6,372,874 shares of Series B Preferred Stock, representing approximately 58.37% of voting power. The Information Statement notes that the corporate actions will not be implemented until at least 20 calendar days after mailing under Rule 14c-2, and that the timing for filing the Certificate of Amendment to effect the authorized-share increase is to be set by the CEO in his sole discretion subject to stated conditions.
PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Defense Tech LLC, furnished information that the subsidiary has secured an exclusive option agreement on a proprietary, U.S.-patented autonomous drone navigation technology for GPS-jammed, spoofed, and denied environments.
The option covers an exclusive license in the aerospace and defense technologies field for specified patent rights tied to U.S. Patent No. 12,277,716 B2, plus a non-exclusive license to related know-how. NorthStrive plans to evaluate the technology, validate defense and counter-drone use cases, and may negotiate a definitive licensing agreement, though there is no guarantee the option will be exercised or that commercialization will succeed.
PMGC Holdings Inc., through its subsidiary SVM Machining, Inc., filed an 8-K to share a press release about a new long-term supply agreement with Turbo-Jet Products Co., Inc. SVM will supply mission-critical aerospace and defense components under a framework covering purchase orders during the agreement’s term.
The agreement has an initial five-year term with provisions for annual renewals, supporting a strategic supply relationship. This is the third long-term agreement signed by a PMGC subsidiary in 2026. SVM is ITAR-registered as of March 20, 2026 and is pursuing AS9100 certification to expand its role in regulated defense programs.